- Reported on the therapeutic benefit of munchies for nausea and vomiting
- Recorded over 14,500 sessions from patients seeking relief from nausea
- Munchies are a medical benefit for those going through chemotherapy or diagnosed with cachexia, also known as a wasting disorder
RYAH Group (CSE: RYAH), the leading data technology company in plant-based medicine, collects data through its IoT dose-measuring devices and AI analytics. Recently the company reported on
The Therapeutic Benefit of the Munchies for Nausea and Vomiting. The full article can be found at
https://ibn.fm/mgkad.
RYAH is uniquely positioned to collect essential data that can lead to more personalized and targeted care within the health industry. The Company partners with doctors, researchers, product suppliers, and retailers to place its top-rated apps, dose-controlled devices and services into the hands of patients and consumers. *The AI platform aggregates and correlates HIPAA-compliant dosing data from seed to consumption, allowing the company to run in-depth analytical reports. These reports help identify trends and consumer outcomes.
Cannabis has always carried a reputation for causing a case of the “munchies.” While some might find this side effect bothersome, others turn to it for that exact reason. Since 2018, RYAH has recorded over 14,500 sessions with patients seeking relief from nausea with medical cannabis.
Currently, cannabis is a patient-driven choice in treating nausea, vomiting, and appetite loss. Of all the conditions that patients turn to medical cannabis for, nausea and vomiting continue to be two of the most socially and legally accepted. It is common for those going through chemotherapy to seek relief and also used by those who have cachexia, a wasting disorder that causes extreme weight loss, nausea and vomiting. As evidence builds through various clinical studies, cannabinoid therapy may soon become a common doctor-recommended prescription rather than merely a patient’s request.
RYAH first developed and commercialized its smart inhaler in 2018. Since then, it has developed a complete IoT device and data analytics platform with multiple delivery mechanisms that include the Smart-Inhaler, Smart Transdermal Patch, and the Smart Pen.
The company has also developed data-driven platforms for doctors and for patients. RYAH MD is a remote and interactive patient-doctor collaboration and dosing administration platform that allows for real-time monitoring, appointment booking, doctor-patient video calls, science-based strain recommendations and more. For the patient and end-user, there is the PotBotApp. This medical cannabis education mobile app creates a personalized and data-driven resource of potential product matches for the user’s ailments and efficacy goals.
RYAH is rapidly expanding and actively looking for partnerships as it takes its data-driven technology and plant-based medicine global.
For more information, visit the company’s website at
www.RYAHGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at
https://ibn.fm/RYAH
